152 related articles for article (PubMed ID: 33239431)
21. Targeting DCAF5 suppresses SMARCB1-mutant cancer by stabilizing SWI/SNF.
Radko-Juettner S; Yue H; Myers JA; Carter RD; Robertson AN; Mittal P; Zhu Z; Hansen BS; Donovan KA; Hunkeler M; Rosikiewicz W; Wu Z; McReynolds MG; Roy Burman SS; Schmoker AM; Mageed N; Brown SA; Mobley RJ; Partridge JF; Stewart EA; Pruett-Miller SM; Nabet B; Peng J; Gray NS; Fischer ES; Roberts CWM
Nature; 2024 Apr; 628(8007):442-449. PubMed ID: 38538798
[TBL] [Abstract][Full Text] [Related]
22. BRG1, the ATPase subunit of SWI/SNF chromatin remodeling complex, interacts with HDAC2 to modulate telomerase expression in human cancer cells.
Wu S; Ge Y; Huang L; Liu H; Xue Y; Zhao Y
Cell Cycle; 2014; 13(18):2869-78. PubMed ID: 25486475
[TBL] [Abstract][Full Text] [Related]
23. EZH2 represses target genes through H3K27-dependent and H3K27-independent mechanisms in hepatocellular carcinoma.
Gao SB; Zheng QF; Xu B; Pan CB; Li KL; Zhao Y; Zheng QL; Lin X; Xue LX; Jin GH
Mol Cancer Res; 2014 Oct; 12(10):1388-97. PubMed ID: 24916103
[TBL] [Abstract][Full Text] [Related]
24. Gene of the month: SMARCB1.
Kalimuthu SN; Chetty R
J Clin Pathol; 2016 Jun; 69(6):484-9. PubMed ID: 26941181
[TBL] [Abstract][Full Text] [Related]
25. Functional relevance of genes predicted to be affected by epigenetic alterations in atypical teratoid/rhabdoid tumors.
Tegeder I; Thiel K; Erkek S; Johann PD; Berlandi J; Thatikonda V; Frühwald MC; Kool M; Jeibmann A; Hasselblatt M
J Neurooncol; 2019 Jan; 141(1):43-55. PubMed ID: 30446899
[TBL] [Abstract][Full Text] [Related]
26. SMARCB1-deficient Tumors of Childhood: A Practical Guide.
Pawel BR
Pediatr Dev Pathol; 2018; 21(1):6-28. PubMed ID: 29280680
[TBL] [Abstract][Full Text] [Related]
27. Loss of IGFBP7 expression and persistent AKT activation contribute to SMARCB1/Snf5-mediated tumorigenesis.
Darr J; Klochendler A; Isaac S; Eden A
Oncogene; 2014 Jun; 33(23):3024-32. PubMed ID: 23851500
[TBL] [Abstract][Full Text] [Related]
28. Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells.
Darr J; Klochendler A; Isaac S; Geiger T; Eden A
Mol Cancer; 2015 Sep; 14():167. PubMed ID: 26370283
[TBL] [Abstract][Full Text] [Related]
29. PRC2-mediated repression of SMARCA2 predicts EZH2 inhibitor activity in SWI/SNF mutant tumors.
Januario T; Ye X; Bainer R; Alicke B; Smith T; Haley B; Modrusan Z; Gould S; Yauch RL
Proc Natl Acad Sci U S A; 2017 Nov; 114(46):12249-12254. PubMed ID: 29087303
[TBL] [Abstract][Full Text] [Related]
30. SMARCB1/INI1 Is Diagnostically Useful in Distinguishing α-Fetoprotein-producing Gastric Carcinoma from Hepatocellular Carcinoma.
Mochizuki K; Kawai M; Odate T; Tahara I; Inoue T; Kasai K; Nakazawa T; Kondo T
Anticancer Res; 2018 Dec; 38(12):6865-6868. PubMed ID: 30504402
[TBL] [Abstract][Full Text] [Related]
31. SMAD dependent signaling plays a detrimental role in a fly model of SMARCB1-deficiency and the biology of atypical teratoid/rhabdoid tumors.
Jeibmann A; Schulz J; Eikmeier K; Johann PD; Thiel K; Tegeder I; Ambrée O; Frühwald MC; Pfister SM; Kool M; Paulus W; Hasselblatt M
J Neurooncol; 2017 Feb; 131(3):477-484. PubMed ID: 28108836
[TBL] [Abstract][Full Text] [Related]
32. HOXA repression is mediated by nucleoporin Nup93 assisted by its interactors Nup188 and Nup205.
Labade AS; Karmodiya K; Sengupta K
Epigenetics Chromatin; 2016; 9():54. PubMed ID: 27980680
[TBL] [Abstract][Full Text] [Related]
33. Cellular senescence regulated by SWI/SNF complex subunits through p53/p21 and p16/pRB pathway.
He L; Chen Y; Feng J; Sun W; Li S; Ou M; Tang L
Int J Biochem Cell Biol; 2017 Sep; 90():29-37. PubMed ID: 28716547
[TBL] [Abstract][Full Text] [Related]
34. Targeting EZH2 in SMARCB1-deficient sarcomas: Advances and opportunities to potentiate the efficacy of EZH2 inhibitors.
Lanzi C; Arrighetti N; Pasquali S; Cassinelli G
Biochem Pharmacol; 2023 Sep; 215():115727. PubMed ID: 37541451
[TBL] [Abstract][Full Text] [Related]
35. SMARCB1 Acts as a Quiescent Gatekeeper for Cell Cycle and Immune Response in Human Cells.
Choi SK; Kim MJ; You JS
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32492816
[TBL] [Abstract][Full Text] [Related]
36. The IL6/JAK/STAT3 signaling axis is a therapeutic vulnerability in SMARCB1-deficient bladder cancer.
Amara CS; Kami Reddy KR; Yuntao Y; Chan YS; Piyarathna DWB; Dobrolecki LE; Shih DJH; Shi Z; Xu J; Huang S; Ellis MJ; Apolo AB; Ballester LY; Gao J; Hansel DE; Lotan Y; Hodges HC; Lerner SP; Creighton CJ; Sreekumar A; Zheng WJ; Msaouel P; Kavuri SM; Putluri N
Nat Commun; 2024 Feb; 15(1):1373. PubMed ID: 38355560
[TBL] [Abstract][Full Text] [Related]
37. SMARCB1 is required for widespread BAF complex-mediated activation of enhancers and bivalent promoters.
Nakayama RT; Pulice JL; Valencia AM; McBride MJ; McKenzie ZM; Gillespie MA; Ku WL; Teng M; Cui K; Williams RT; Cassel SH; Qing H; Widmer CJ; Demetri GD; Irizarry RA; Zhao K; Ranish JA; Kadoch C
Nat Genet; 2017 Nov; 49(11):1613-1623. PubMed ID: 28945250
[TBL] [Abstract][Full Text] [Related]
38. BAFfling pathologies: Alterations of BAF complexes in cancer.
Arnaud O; Le Loarer F; Tirode F
Cancer Lett; 2018 Apr; 419():266-279. PubMed ID: 29374542
[TBL] [Abstract][Full Text] [Related]
39. SMARCB1 loss interacts with neuronal differentiation state to block maturation and impact cell stability.
Parisian AD; Koga T; Miki S; Johann PD; Kool M; Crawford JR; Furnari FB
Genes Dev; 2020 Oct; 34(19-20):1316-1329. PubMed ID: 32912900
[TBL] [Abstract][Full Text] [Related]
40. SWI/SNF Complex-deficient Undifferentiated/Rhabdoid Carcinomas of the Gastrointestinal Tract: A Series of 13 Cases Highlighting Mutually Exclusive Loss of SMARCA4 and SMARCA2 and Frequent Co-inactivation of SMARCB1 and SMARCA2.
Agaimy A; Daum O; Märkl B; Lichtmannegger I; Michal M; Hartmann A
Am J Surg Pathol; 2016 Apr; 40(4):544-53. PubMed ID: 26551623
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]